Who are we?
GamaMabs Pharma is a clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer. GamaMabs’ lead project is the monoclonal antibody (mAb) GM102 which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in cancer. The company develops low-fucose EMABling® antibodies with increased tumor cell killing properties through the activation of immune system cells. GamaMabs has a licensing agreement with MedImmune (USA) to develop an Antibody Drug Conjugate targeting cancer.